TopoTarget executes its licensing option for Zenmab development

TopoTarget A/S has executed its in-licensing option from Novartis Pharma AG of Switzerland, for the development and

marketing of Zemab®, an antibody based anti-cancer drug. According to the option and licensing agreement originating from 2003, TopoTarget now holds the world-wide and exclusive rights for the development of this product.

"I am happy to announce execution of this option. Zemab® has shown potential as a cancer drug in our preclinical models - and in a pilot study where Zemab® was injected directly into tumors in cancer patients with responses seen in 6 out of 10 patients. Zemab® has also successfully been evaluated in a phase I i.v. clinical trial. We are now ready to proceed in the development of Zemab® and next step will be to explore the possibilities in treating breast cancer patients," says Peter Buhl Jensen, CEO of TopoTarget.

Source: Press release TopoTarget, 12.03.07.

Read the press release at the TopoTarget homepage.